Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.56 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 11/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.49 |
| ▸ | FLT1 | P17948 | 6/20 | 0.49 |
| ▸ | FLT4 | P35916 | 6/20 | 0.49 |
| ▸ | AXL | P30530 | 2/20 | 0.49 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.49 |
| ▸ | MERTK | Q12866 | 2/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | CIT | O14578 | 1/20 | 0.47 |
| ▸ | GAK | O14976 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4417734 | 0.90 | EGFR (0.61) | KDREPHA2EPHB4ERBB2EGFR | |
| SCHEMBL4690822 | 0.87 | ENPP1 (0.47) | KDREPHA2EPHB4ERBB2ENPP1 | |
| SCHEMBL4687074 | 0.86 | KDR (0.60) | KDRENPP1EGFRFGFR1FLT1 | |
| SCHEMBL3166753 | 0.84 | PDE5A (0.57) | KDRENPP1EGFRSRCGAK | |
| SCHEMBL30103402 | 0.84 | PDE5A (0.57) | KDRENPP1EGFRSRCGAK | |
| SCHEMBL16760390 | 0.84 | ENPP1 (0.68) | KDREPHA2EPHB4ERBB2ENPP1 | |
| SCHEMBL4689911 | 0.82 | EPHA2 (0.61) | KDREPHA2EPHB4ERBB2EGFR | |
| SCHEMBL15127844 | 0.81 | ENPP1 (0.68) | KDREPHB4ENPP1EGFRSRC | |
| SCHEMBL5828984 | 0.81 | EPHA2 (0.50) | KDREPHA2EPHB4ERBB2ENPP1 | |
| SCHEMBL4691126 | 0.81 | EPHA2 (0.58) | KDREPHA2EPHB4ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| EP-1296973-B1 | GUANIDINE DERIVATIVES OF QUINAZOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| US-7001904-B1 | Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| EP-1296973-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AstraZeneca AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| EP-1272185-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1218353-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca UK Limited (GB) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | KDR 39/4885EPHA2 2239/4885EPHB4 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.